SeQuent Scientific Ltd
NSE:SEQUENT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
126.68
252
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
SeQuent Scientific Ltd
SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2016-03-10. The firm operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The firm through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.
SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2016-03-10. The firm operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The firm through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.
Merger Approved: The National Company Law Tribunal has approved the merger between SeQuent Scientific and Viyash Life Sciences, setting the stage for integration and growth.
Revenue Growth: SeQuent reported Q2 FY '26 revenue of INR 4,240 million, up 15% year-on-year, driven by strong performance in formulations and APIs.
Margin Expansion: Gross margin improved by 270 basis points to 49.7%, and adjusted EBITDA rose 47% to INR 657 million, with margins reaching 15.5%.
Profit Surge: Profit after tax nearly tripled year-on-year to INR 196 million for the quarter.
Viyash Record Performance: Viyash posted record quarterly revenue and EBITDA, with margins jumping from 17.5% to 28.8%.
Sustained Double-Digit Outlook: Management indicated confidence in sustaining double-digit revenue growth and 20%+ EBITDA margins going forward.
Synergy Benefits: Integration is expected to bring significant R&D, manufacturing, and procurement synergies, with most cost and margin improvements to be realized over the next 12-18 months.
Strong Balance Sheet: Focus remains on deleveraging, maximizing free cash flow, and supporting both organic and inorganic growth.
